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(P=0.008). Statistical significance was lost when adjust›
ment was made for ulceration and then for maximum
diameter. We found no evidence that surgeons in any
of the three categories who performed more than six
primary melanoma excisions annually had better
outcomes than those who performed fewer excisions.
Comment
Survival of melanoma patients does not depend on the
surgical background of the person removing the
primary tumour. The object of this study was to
provide an evidence base for primary care guidelines
on appropriate specialist referral. The data show that
the growth in dermatological surgeons excising
primary melanomas has had no adverse affect on
patient outcome. We found no evidence that any type
of surgeon performing excisions of primary melano›
mas regularly had a better outcome than those who
carried out fewer excisions, possibly because wide local
excision is a relatively simple procedure. We therefore
provide an evidence base to recommend referral of
suspected primary melanomas to the dermatological,
plastic surgery, or general surgical service with the
shortest surgical waiting time.
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Drug points
Dysgeusia and burning mouth syndrome by
eprosartan
Xavier Castells, Isidre Rodoreda, Consuelo Pedrós, Gloria Cereza,
Joan›Ramon Laporte
Eprosartan is an angiotensin II receptor antagonist.
Dysgeusia and burning mouth syndrome attributed to
angiotensin converting enzyme inhibitors have been
reported.1 Several case reports related to angiotensin II
receptor antagonists have also been published. We report
the case of a patient in whom oral eprosartan induced
reversible taste disturbance and burning mouth sensation
on two occasions. This case was reported to the Catalan
pharmacovigilance centre.
A 48 year old woman with a 10 year history of essen›
tial hypertension was being treated with valsartan 160 mg
daily. She had no other medical condition and was not
taking any other drugs. She started taking eprosartan
600 mg daily because her blood pressure remained
uncontrolled with valsartan. Three weeks later she
complained of a metallic taste and a burning sensation in
her mouth. The oral cavity was normal and no underlying
medical causes were identified. She stopped taking
eprosartan and one week later her taste had returned to
normal. The dysgeusia was not attributed to eprosartan
and she started taking the drug again. A few days later,
dysgeusia and the burning sensation in her mouth
returned. She stopped taking eprosartan and her taste
recovered in two days.
Taste disorders related to angiotensin II receptor
antagonists had not been described in clinical trials,2 but
several cases of dysgeusia have been reported in patients
treated with losartan3–5 and with valsartan.6 To our knowl›
edge, this is the first reported case of dysgeusia induced by
eprosartan and the first case of dysgeusia induced by
angiotensin II receptor antagonists with positive rechal›
lenge. Dysgeusia with losartan but not with angiotensin
converting enzyme inhibitors has been reported to occur
in the same patient, suggesting that angiotensin convert›
ing enzyme inhibitors or angiotensin II receptor
antagonists produce this effect by acting through different
mechanisms.5 Because the incidence of dysgeusia in
patients treated with drugs from these two therapeutic
groups is low,1 2 it is possible that this adverse effect
appears only in patients with some predisposing
condition.
In our case report, the temporal sequence of events—
and, in particular, positive rechallenge—and the lack of
underlying concomitant diseases or other drugs strongly
suggest that the association between dysgeusia, burning
mouth syndrome, and eprosartan was causal. Because
these effects occurred with eprosartan but not with valsar›
tan at equivalent doses, however, our observation does not
favour the theory of an effect due to the angiotensin II
receptor antagonist class of drug. Factors predisposing to
this adverse effect remain to be identified and the
mechanism remains to be elucidated.
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